The attenuation of spine and hip BMD decline after 3-year IAST compared with those reported for continuous AST appears to be due to testosterone driven BMD recovery in the POST period. Failure of testosterone recovery was associated with worse final BMD. By reducing the potential risk for adverse bone complications, intermittent therapy may become an important consideration when the therapeutic ratio is narrow.
No takes yet. Share an insight, caveat, or question.
Spry et al. (2009) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: